Companies / DXCM vs BSX
DXCM vs BSX: Dexcom and Boston Scientific
Dexcom (DXCM) reported $4.7B in revenue against a 17.9% net margin, while Boston Scientific (BSX) reported $20.1B at a 14.4% net margin, most recently.
| Metric | DXCM | BSX |
|---|---|---|
| Revenue | $4.7B | $20.1B |
| Net Income | $0.8B | $2.9B |
| Gross Margin | 60.1% | 69.0% |
| Operating Margin | 19.6% | 18.0% |
| EPS (Diluted) | $2.09 | $1.94 |
| Free Cash Flow | $1.1B | $3.7B |
| Total Debt | $1.3B | $11.4B |
| P/E Ratio | 31.8× | 49.2× |
| P/B Ratio | 9.3× | n/m |
| Stock Price | $84.45 | $44.62 |
Free: last 5 years
| Fiscal year | FY2009 🔒 | FY2010 🔒 | FY2011 🔒 | FY2012 🔒 | FY2013 🔒 | FY2014 🔒 | FY2015 🔒 | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DXCM Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $2.4B | $2.9B | $3.6B | $4.0B | $4.7B |
| BSX Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $11.9B | $12.7B | $14.2B | $16.7B | $20.1B |